Palvella Therapeutics Inc.
PVLA | NASDAQ
$159.21
+$5.80 (+3.78%)
Sep 22, 2026, 2:07 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -28.21 | -1.53 | 1.15 | -0.57 | -0.30 | n/a |
PEG Ratio | 0.54 | 0.01 | -0.01 | 0.01 | n/a | n/a |
PS Ratio | n/a | n/a | n/a | 0.61 | 0.44 | n/a |
PB Ratio | 42.09 | 0.43 | -5.56 | -0.68 | 0.27 | n/a |
P/FCF Ratio | -47.10 | -2.46 | -1.57 | -1.07 | -1.59 | n/a |
P/OCF Ratio | -47.10 | -2.46 | -1.57 | -1.07 | -1.79 | n/a |
OCF/S Ratio | n/a | n/a | n/a | -57.29 | -24.38 | n/a |
Debt / Equity Ratio | 0.02 | n/a | n/a | n/a | 0.29 | 0.55 |
Quick Ratio | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 | 3.42 |
Current Ratio | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 | 3.42 |
Asset Turnover | n/a | n/a | n/a | 1.57 | 0.20 | n/a |
Interest Coverage | -6.63 | -3.26 | n/a | n/a | n/a | n/a |
Return on Equity | -149.07% | -27.85% | -481.73% | 143.60% | -90.12% | n/a |
Return on Assets | -70.04% | -19.76% | 247.63% | -201.39% | -29.79% | n/a |
Return on Invested Capital | -79.73% | -18.50% | -228.78% | -404.71% | -49.81% | n/a |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | 89.27% | 92.46% | n/a |
Net Profit Margin | n/a | n/a | n/a | -128.47% | -145.58% | n/a |
Pretax Profit Margin | n/a | n/a | n/a | -128.47% | -145.58% | n/a |
Operating Profit Margin | n/a | n/a | n/a | -167.84% | -164.97% | n/a |
FCF Margin | n/a | n/a | n/a | -57.29% | -27.40% | n/a |
EBITDA Margin | n/a | n/a | n/a | -117.74% | -138.04% | n/a |
Add to Watchlist
Select watchlists to add or remove PVLA